Efficacy and safety of lebrikizumab in adult patients with mild-to-moderate asthma not receiving inhaled corticosteroids.

Journal: Respiratory medicine
PMID: 29413502

Abstract

BACKGROUND: Asthma is a heterogeneous and complex disease in both its clinical course and response to treatment. IL-13 is central to Type 2 inflammation and contributes to many features of asthma. In a previous Phase 2 study, lebrikizumab, an anti-IL-13 monoclonal antibody, did not significantly improve FEV in mild-to-moderate asthma patients not receiving ICS therapy. This Phase 3 study was designed to further assess the efficacy and safety of lebrikizumab in adult patients with mild-to-moderate asthma treated with daily short-acting β-agonist therapy alone.

Authors

  • Philip Korenblat
    The Clinical Research Centre LLC, St Louis, MO, USA.
  • Edwin Kerwin
    Clinical Research Institute of Southern Oregon PC, Medford, OR, USA.
  • Igor Leshchenko
    Ural State Medical University, Yekaterinburg, Russia.
  • Karl Yen
    Genentech, Inc., South San Francisco, CA, USA.
  • Cecile T J Holweg
    Genentech, Inc., South San Francisco, CA, USA.
  • Judith Anzures-Cabrera
    Roche Products Limited, Welwyn Garden City, UK.
  • Carmen Martin
    Roche Products Limited, Welwyn Garden City, UK.
  • Wendy S Putnam
    Genentech, Inc., South San Francisco, CA, USA.
  • Laura Governale
    Genentech, Inc., South San Francisco, CA, USA.
  • Julie Olsson
    Genentech, Inc., South San Francisco, CA, USA.
  • John G Matthews
    Genentech, Inc., South San Francisco, CA, USA. Electronic address: matthews.john@gene.com.

Keywords

External Resources

Popular Topics
Recent Journals